Recurrent Ovarian Cancer — Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer
Citation(s)
Beatriz M Carreno, Vincent Magrini, Michelle Becker-Hapak, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015, 348(6236):803-808.
Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft LE Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov. 2020 Sep;19(9):635-652. doi: 10.1038/s41573-020-0074-8. Epub 2020 Aug 6. Review.
Janos L Tanyi, Sara Bobisse, Eran Ophir, et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Transl. Med. 10, eaao5931 (2018)
Linda M Liau, Keyoumars Ashkan, David D Tran, et al First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018, 16(1):142-151.
S ´ebastien Anguille, Ann L Van de Velde, Evelien L. Smits, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. BLOOD, 12 OCTOBER 2017 x VOLUME 130, NUMBER 15:1713-1721.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
